ALTOPREV™ (Lovastatin) Extended-Release Tablets contain a cholesterol-lowering agent isolated from a strain of
Aspergillus terreus. After oral ingestion, lovastatin, which is an inactive lactone, is hydrolyzed to the corresponding (beta)-hydroxyacid form. This is a principal metabolite and inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol.
Therapy with ALTOPREV™ (Lovastatin) Extended-Release Tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia who are at risk for atherosclerotic vascular disease. ALTOPREV™ should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower Total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk.
ALTOPREV™ is indicated for the following:
Primary Prevention of Coronary Heart Disease
In individuals without symptomatic cardiovascular disease, average to moderately elevated Total-C and LDL-C, and below average HDL-C, ALTOPREV™ is indicated to reduce the risk of:
Coronary revascularization procedures
(See CLINICAL PHARMACOLOGY, Clinical Studies.)
Coronary Heart Disease
ALTOPREV™ is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels.
Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia
ALTOPREV™ is indicated as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb, see Table VI) when the response to diet restricted in saturated fat and cholesterol and to other non-pharmacological measures alone has been inadequate.
Published Studies Related to Altoprev (Lovastatin)
Augmentation of fluoxetine with lovastatin for treating major depressive
disorder, a randomized double-blind placebo controlled-clinical trial. 
BACKGROUNDS: There are contradictory evidence about the effect of statins on
depression. This 6-week-randomized placebo-controlled clinical trial assessed the
efficacy and safety of lovastatin as an adjuvant agent for treating major
depressive disorder (MDD)... DISCUSSION: These results suggest that lovastatin as an adjuvant treatment may be
effective for treating patients with MDD.
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. [2011.10]
The treatment of patients with multiple myeloma usually includes many drugs including thalidomide, lenalidomide and bortezomib.Our results suggest that the addition of lovastatin to the TD regimen may improve the response rate in patients with relapsed or refractory myeloma.
Influence of one-year treatment with lovastatin on myocardial remodeling and ischemia in patients with coronary artery disease. [2011.02]
OBJECTIVE: Emerging evidence assumes that statins have a benefit to influence the myocardial remodeling and ischemia in patients with coronary artery disease (CAD). Our aim was to investigate the possible and direct favorable effects of lovastatin on left ventricular (LV) systolic, diastolic function and myocardial ischemia in patients with CAD... CONCLUSION: Lipid-lowering therapy with lovastatin improved the LV systolic function and decreased myocardial ischemia.
Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. [2010.03]
BACKGROUND: Lovastatin is an inhibitor of P-glycoprotein (P-gp) and is metabolized by the cytochrome P450 (CYP) 3A4 isoenzyme. Verapamil is a substrate of both P-gp and CYP3A4. It is therefore likely that lovastatin can alter the absorption and metabolism of verapamil... CONCLUSION: Lovastatin increased the absorption of verapamil by inhibiting P-gp and inhibited the first-pass metabolism of verapamil by inhibiting CYP3A4 in the intestine and/or liver in humans.
Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. [2010.01]
BACKGROUND: Chronic kidney disease (CKD) is associated with an increased risk of incident cardiovascular disease (CVD); however, the role of statins for the primary prevention of acute cardiovascular events in patients with CKD and the effect of statins on kidney function loss in persons without prevalent CVD have not been studied... CONCLUSIONS: Lovastatin is effective for the primary prevention of CVD in patients with CKD, but is not effective in decreasing kidney function loss in persons with no CVD. Copyright 2009 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Clinical Trials Related to Altoprev (Lovastatin)
Fed Bioavailability Study of Lovastatin Tablets and Mevacor Tablets [Completed]
Pre-Prostatectomy Lovastatin on Prostate Cancer [Recruiting]
To determine the dose of continuous daily oral lovastatin needed to achieve MYC [v-myc
myelocytomatosis viral oncogene homolog (avian)] down-regulation in prostatectomy specimens
in intermediate-/high-risk localized prostate cancer patients.
Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis [Recruiting]
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 [Recruiting]
The specific aim of this study is to determine whether Lovastatin ™ significantly improves
visual spatial learning and/or sustained attention in children with NF1.
To evaluate the effect of Lovastatin ™ on measures of executive function, behavior and
quality of life in children with NF1 and cognitive deficits.
To further evaluate the toxicity and tolerability of Lovastatin ™ in children with NF1 and
It is hypothesized that Lovastatin ™ will improve the visual spatial memory and/or
attention deficits in children with NF1. This is based on studies demonstrating that
Lovastatin ™ has significantly improved impairments in visual spatial memory and attention
in the NF1 murine model.
It is further expected that Lovastatin ™ will be safe and well tolerated over a 16-week
Lovastatin as a Potential Modulator of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD) [Recruiting]
This study will test whether lovastatin helps to modify lung inflammation in patients with
COPD (Chronic Obstructive Pulmonary Disease).